Date: 2011-02-09
Type of information: Company acquisition
Acquired company: Kinaxo (Germany)
Acquiring company: Evotec (Germany)
Amount: €12 million
Terms: Evotec AG has signed a definitive agreement to acquire all shares in Kinaxo Biotechnologies. The acquisition of Kinaxo confirms Evotec\'s leading position as fully integrated drug discovery and early development partner for pharma and biotechnology companies. Integration of Kinaxo\'s novel technologies enables Evotec and its partners to take earlier educated decisions on drug efficacy, safety and response in patients. It adds to Evotec platforms proprietary technologies for response prediction and drug efficacy and safety assessment; especially in key indication area oncology.
Kinaxo's innovative technologies include: - Cellular Target Profiling® uncovers the molecular targets of compounds with unknown mode-of-action and reveals possible off-target side effects early in the discovery and development process.
- KinAffinity® determines the cellular selectivity of kinase inhibitors, which represent the most important class of targeted cancer drugs.
- PhosphoScout® provides valuable knowledge on drug modes-of-action in vivo and how they respond to drug treatment.
Details:
Related: Drug discovery
Drug development
Oncology
